Core Viewpoint - The stock of Jiangjie Ankang-B (02617.HK) has experienced a dramatic surge, with a price increase of over 130% in a single day and a total rise of 18 times since its listing, driven by the announcement of clinical trial approval for its core product, Tinengotinib, for breast cancer treatment [1][2]. Company Overview - Jiangjie Ankang-B was listed on the Hong Kong Stock Exchange on June 23, with an initial offering price of HKD 13.15 per share, raising approximately HKD 201 million [3]. - The company reported a pre-tax loss of HKD 1.23 billion for the first half of 2024, an improvement from HKD 1.6 billion in the same period the previous year [4]. Product Development - The company’s core product, Tinengotinib (TT-00420), has received clinical approval for a Phase II trial in China, targeting HR+/HER2- breast cancer patients who have failed previous treatments [1][2]. - Early clinical results indicate promising efficacy for Tinengotinib, particularly in combination with Fulvestrant, showcasing a pharmacological synergy that may offer new treatment options for difficult-to-treat cancers [2][4]. Market Performance - The stock has seen extreme volatility, with a peak price of HKD 251.4 per share, followed by a significant drop, indicating potential risks associated with rapid price increases [5]. - The stock was included in the Hong Kong Stock Connect program, effective September 8, which may enhance its trading volume and investor interest [5].
刷屏！暴涨超130%，发生了什么？